eligibility_summary
Adults ≥18, ECOG 0–1 with advanced/metastatic CDH3+ solid tumors, refractory or intolerant to standard care, measurable disease (RECIST 1.1), tumor tissue available, life expectancy ≥3 months, adequate organ function, contraception, consent. Exclude: pregnancy, recent therapy/radiation, immunosuppression, active CNS mets, infection, ILD/pneumonitis, uncontrolled HTN/CV disease, corneal disease, ≥G2 neuropathy, strong CYP3A4 drugs, transplant, hypersensitivity, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: BC3195, an intravenous antibody–drug conjugate (ADC). Mechanism: A monoclonal antibody targets CDH3 (P-cadherin) on tumor cells, upon binding and internalization, a cathepsin-cleavable Val-Cit linker releases the payload MMAE (monomethyl auristatin E), a microtubule-disrupting agent that inhibits tubulin polymerization, causing G2/M arrest and apoptosis, membrane-permeable MMAE may confer a bystander effect. Targets: CDH3-overexpressing epithelial tumor cells seen in HNSCC, ESCC, breast, NSCLC, endometrial, urothelial, colorectal, ovarian, pancreatic, and prostate cancers. Pathways/cellular processes: cadherin-mediated cell-surface receptor internalization, microtubule/mitotic spindle dynamics and cell-cycle progression. Phase: Ia/Ib dose escalation/expansion.